Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages 1620-1626

  Maurer, Matthew J ^a,b,c   Micallef, Ivana N M ^a,b,c   Cerhan, James R ^a,b,c   Katzmann, Jerry A ^a,b,c   Link, Brian K ^a,b,c   Colgan, Joseph P ^a,b,c   Habermann, Thomas M ^a,b,c   Inwards, David J ^a,b,c   Markovic, Svetomir N ^a,b,c   Ansell, Stephen M ^a,b,c   Porrata, Luis F ^a,b,c   Johnston, Patrick B ^a,b,c   Nowakowski, Grzegorz S ^a,b,c   Thompson, Carrie A ^a,b,c   Gupta, Mamta ^a,b,c   Syrbu, Sergei I ^a,b,c   Kurtin, Paul J ^a,b,c   Macon, William R ^a,b,c   Nikcevich, Daniel A ^a,b,c   Witzig, Thomas E ^a,b,c,d  

^a Mayo Clinic College of Medicine   (United States)

^b Duluth Community Clinical Oncology Program   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; COHORT ANALYSIS; EVENT FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOLOGIC TECHNIQUES; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UP-REGULATION; YOUNG ADULT;

EID: 79955033395     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.4413     Document Type: Article

References (29)

1. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006 (Pubitemid 46638950)
2. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
3. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007 (Pubitemid 46348180)
4. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000 (Pubitemid 30082188)
5. Choi WW, Weisenburger DD, Greiner TC, et al: A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15:5494-5502, 2009
6. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004 (Pubitemid 38029949)
7. Bradwell AR, Carr-Smith HD, Mead GP, et al: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47:673-680, 2001 (Pubitemid 32275810)
8. Katzmann JA, Abraham RS, Dispenzieri A, et al: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51:878-881, 2005 (Pubitemid 40577925)
9. Rajkumar SV, Kyle RA, Therneau TM, et al: Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106:812-817, 2005 (Pubitemid 41076419)
10. Dingli D, Kyle RA, Rajkumar SV, et al: Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 108:1979-1983, 2006 (Pubitemid 44395010)
11. Abraham RS, Katzmann JA, Clark RJ, et al: Quantitative analysis of serum free light chains: A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 119:274-278, 2003 (Pubitemid 37047884)
12. Dispenzieri A, Kyle R, Merlini G, et al: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215-224, 2009
13. Dispenzieri A, Lacy MQ, Katzmann JA, et al: Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107:3378-3383, 2006
14. Gottenberg JE, Aucouturier F, Goetz J, et al: Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 66:23-27, 2007 (Pubitemid 46044856)
15. Diamantidis MD, Ioannidou-Papagiannaki E, Ntaios G: Novel extended reference range for serum kappa/lambda free light chain ratio in diagnosing monoclonal gammopathies in renal insufficient patients. Clin Biochem 42:1202-1203, 2009
16. Martin W, Abraham R, Shanafelt T, et al: Serum-free light chain-A new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res 149:231-235, 2007 (Pubitemid 46442009)
17. Pratt G, Harding S, Holder R, et al: Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol 144:217-222, 2009
18. Yegin ZA, Ozkurt ZN, Yagci M: Free light chain: A novel predictor of adverse outcome in chronic lymphocytic leukemia. Eur J Haematol 84: 406-411, 2010
19. Landgren O, Goedert JJ, Rabkin CS, et al: Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 28:773-779, 2010
20. Micallef IN, Maurer MJ, Witzig TE, et al: PET scan results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Blood 114:137, 2009 (abstr 137)
21. Micallef IN, Maurer MJ, Nikcevich DA, et al: Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol 27:436s, 2009 (abstr 8508)
22. Swerdlow SH, Campo E, Harris NL, et al: WHO classification of tumours of haematopoietic and lymphoid tissues, in Bosman FT, Jaffe ES, Lakhani SR, et al (eds): World Health Organization Classification of Tumours (ed 4). Lyon, France, International Agency for Research on Cancer, 2008, pp 233-237
23. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
24. Cheson B, Horning S, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253, 1999 (Pubitemid 29162950)
25. Katzmann JA, Clark RJ, Abraham RS, et al: Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 48:1437-1444, 2002 (Pubitemid 34925779)
26. Cox D: Regression models and life tables (with discussion). Journal of the Royal Statistical Society B 34:187-220, 1972
27. Kaplan E, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481, 1958
28. Eilers PH, Marx BD Flexible smoothing with B-splines and penalties Stat Sci 11 89-121 1996. (Pubitemid 126706128)
29. Heagerty PJ, Zheng Y Survival model predictive accuracy and ROC curves Biometrics 61 92-105 2005. (Pubitemid 40380968)